Quoin Pharmaceuticals (QNRX) Net Income towards Common Stockholders (2021 - 2023)

Quoin Pharmaceuticals has reported Net Income towards Common Stockholders for 3 years, with the latest figure at -$2.0 million in Q4 2023.

• Quarterly Net Income towards Common Stockholders fell 2.44% year-over-year to -$2.0 million in Q4 2023, while the trailing twelve-month figure through Sep 2024 was -$2.0 million (up 47.81% YoY) and the FY2023 annual result came in at -$8.7 million, up 8.05% from the prior year.
• Net Income towards Common Stockholders slipped to -$2.0 million in Q4 2023 per QNRX's latest filing, from -$1.9 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at -$1.4 million in Q3 2021 and troughed at -$11.8 million in Q4 2021.
• A 3-year average of -$3.7 million and a median of -$2.0 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• The widest YoY moves for Net Income towards Common Stockholders: up 83.07% in 2022, down 120.41% in 2022.
• Over 3 years, Net Income towards Common Stockholders stood at -$11.8 million in 2021, then jumped by 83.07% to -$2.0 million in 2022, then slipped by 2.44% to -$2.0 million in 2023.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$2.0 million, -$1.9 million, and -$2.0 million for Q4 2023, Q3 2023, and Q4 2022 respectively.